4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-22-055138
Chief Scientific Officer sold 1,165 shares at $12.88 ($15,006)
- Chief Scientific Officer acquired 3,207 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-10-30 | Exercise or conversion : show line 1 in the form | +3,207 | 22,379 | D | ||
| 2022-10-31 | Sale : show line 2 in the form | −1,165 | $12.88 | $15,006 | 21,214 | D |
| Open-market sales · 1,165 sh · avg $12.88 · $15,006 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-10-30 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −3,207 | 41,688 | D |
Loading xslF345X03/doc4.xml…